
Few Alzheimer's Patients Eligible for New Drug
The story in brief
A study found that only 134 out of 643 patients with Alzheimer's or mild cognitive impairment were eligible for lecanemab treatment. Confirming amyloid pathology, which involves abnormal protein buildup, is critical but limited to research settings. Early diagnosis allows doctors to assess health and determine treatment appropriateness, though advanced disease and comorbidities often exclude patients.